Labetalol Hydrochloride
FDA-approved product (injectable, injection), marketed as Labetalol Hydrochloride, Labetalol Hydrochloride In Dextrose, Labetalol Hydrochloride In Sodium Chloride and 2 more.
- Registered studies
- 12
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Hypertension
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Alpha and beta blocking agents
- FDA pharmacologic class
- beta-Adrenergic Blocker FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Labetalol Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA28.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae9.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
12registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Labetalol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome60.5% AI-predicted activityagainst E. coli50+ registered studies
- PlecanatideExisting use: Constipation60.1% AI-predicted activityagainst E. coli15 registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia60.0% AI-predicted activityagainst E. coli41 registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.6% AI-predicted activityagainst E. coli50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma59.6% AI-predicted activityagainst E. coli2 registered studies
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances59.5% AI-predicted activityagainst E. coli50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more59.4% AI-predicted activityagainst E. coli5 registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst E. coli50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more59.0% AI-predicted activityagainst E. coli50+ registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more58.8% AI-predicted activityagainst E. coli10 registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.8% AI-predicted activityagainst E. coli7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Hypotensive Anesthesia for Orthognathic Surgery
NCT06093893 · start 2025-03-04
Registered record
- Registry ID
- NCT06093893
- Conditions
- Hypotensive Anesthesia; Orthognathic Surgery
- Interventions
- Dexmedetomidine; Nicardipine; Labetalol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2025-03-04
- Completion
- 2026-02-06
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypotensive Anesthesia; Orthognathic SurgeryInterventionDexmedetomidine; Nicardipine; LabetalolPhasePhase 4Registry statusCompletedIs Labetalol More Effective Than Metoprolol for Controlled Hypotensive Anesthesia During Endoscopic Nasal Surgeries?
NCT05368376 · start 2021-04-01
Registered record
- Registry ID
- NCT05368376
- Conditions
- Hypotension Drug-Induced
- Interventions
- Labetalol Hydrochloride Oral Tablet; Metoprolol Tartrate Oral Tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2021-04-01
- Completion
- 2022-10-15
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypotension Drug-InducedInterventionLabetalol Hydrochloride Oral Tablet; Metoprolol Tartrate Oral TabletPhasePhase 4Registry statusCompletedPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404 · start 2020-03-05
Registered record
- Registry ID
- NCT04278404
- Conditions
- Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2020-03-05
- Completion
- 2026-12
- Enrolment
- 5,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 moreInterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:PhaseNot recordedRegistry statusRecruitingPharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
NCT03511118 · start 2018-10-04
Registered record
- Registry ID
- NCT03511118
- Conditions
- Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
- Interventions
- Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2018-10-04
- Completion
- 2028-07-31
- Enrolment
- 1,600
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOIInterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 morePhaseNot recordedRegistry statusRecruitingUse of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients
NCT03105661 · start 2017-04-04
Registered record
- Registry ID
- NCT03105661
- Conditions
- Obesity, Morbid; Preeclampsia
- Interventions
- Labetalol Hydrochloride 200 mg; NIFEdipine 60 mg; Atenolol 25 mg
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Unknown
- Start
- 2017-04-04
- Completion
- 2020-03-04
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionObesity, Morbid; PreeclampsiaInterventionLabetalol Hydrochloride 200 mg; NIFEdipine 60 mg; Atenolol 25 mgPhaseEarly phase 1Registry statusUnknownOral Nifedipine Versus IV Labetalol in Severe Pre Eclampsia
NCT03325348 · start 2017-02-23
Registered record
- Registry ID
- NCT03325348
- Conditions
- Severe Pre-Eclampsia, Antepartum
- Interventions
- Nifedipine 10 mg; Labetalol
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Unknown
- Start
- 2017-02-23
- Completion
- 2018-01-15
- Enrolment
- 194
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSevere Pre-Eclampsia, AntepartumInterventionNifedipine 10 mg; LabetalolPhasePhase 2 / Phase 3Registry statusUnknownEnhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
NCT01422616 · start 2012-03
Registered record
- Registry ID
- NCT01422616
- Conditions
- Ischemic Stroke; High Blood Pressure
- Interventions
- Low-dose rtPA; Standard-dose rtPA; Intensive blood pressure (BP) lowering; BP management policies
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2018-08
- Enrolment
- 4,587
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIschemic Stroke; High Blood PressureInterventionLow-dose rtPA; Standard-dose rtPA; Intensive blood pressure (BP) lowering; BP management policiesPhasePhase 3Registry statusCompletedPharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
NCT01431326 · start 2011-11
Registered record
- Registry ID
- NCT01431326
- Conditions
- Adenovirus; Anesthesia; Anxiety; Anxiolysis; Autism; Autistic Disorder; Bacterial Meningitis; Bacterial Septicemia; Benzodiazepine; Bipolar Disorder; Bone and Joint Infections; Central Nervous System Infections; Convulsions; Cytomegalovirus Retinitis; Early-onset Schizophrenia Spectrum Disorders; Epilepsy; General Anesthesia; Gynecologic Infections; Herpes Simplex Virus; Infantile Hemangioma; Infection; Inflammation; Inflammatory Conditions; Intra-abdominal Infections; Lower Respiratory Tract Infections; Migraines; Pain; Pneumonia; Schizophrenia; Sedation; Seizures; Skeletal Muscle Spasms; Skin and Skin-structure Infections; Treatment-resistant Schizophrenia; Urinary Tract Infections; Withdrawal; Sepsis; Gram-negative Infection; Bradycardia; Cardiac Arrest; Cardiac Arrhythmia; Staphylococcal Infections; Nosocomial Pneumonia; Neuromuscular Blockade; Methicillin Resistant Staphylococcus Aureus; Endocarditis; Neutropenia; Headache; Fibrinolytic Bleeding; Pulmonary Arterial Hypertension; C
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2011-11
- Completion
- 2019-11
- Enrolment
- 3,520
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenovirus; Anesthesia; Anxiety; Anxiolysis +47 moreInterventionThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:PhaseNot recordedRegistry statusCompletedAntihypertensive Treatment of Acute Cerebral Hemorrhage-II
NCT01176565 · start 2011-05-15
Registered record
- Registry ID
- NCT01176565
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Intravenous nicardipine hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2011-05-15
- Completion
- 2016-03-08
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntracerebral HemorrhageInterventionIntravenous nicardipine hydrochloridePhasePhase 3Registry statusTerminatedEvaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department
NCT00765648 · start 2008-10
Registered record
- Registry ID
- NCT00765648
- Conditions
- Hypertensive Urgency
- Interventions
- nicardipine intravenous; Labetalol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2010-01
- Enrolment
- 226
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensive UrgencyInterventionnicardipine intravenous; LabetalolPhasePhase 4Registry statusCompletedThe Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
NCT00716079 · start 2008-09
Registered record
- Registry ID
- NCT00716079
- Conditions
- Intracerebral Hemorrhage; Stroke; Hypertension
- Interventions
- Blood pressure management policies
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2012-12
- Enrolment
- 2,839
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntracerebral Hemorrhage; Stroke; HypertensionInterventionBlood pressure management policiesPhaseNot applicableRegistry statusCompletedIntensive Blood Pressure Reduction in Acute Cerebral Haemorrhage
NCT00226096 · start 2005-11
Registered record
- Registry ID
- NCT00226096
- Conditions
- CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages
- Interventions
- Labetalol Hydrochloride; Metoprolol tartrate; Hydralazine Hydrochloride; Glycerol Trinitrate; Phentolamine mesylate; Nicardipine; Urapidil; Esmolol; Clonidine; Enalaprilat; Nitroprusside
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2007-09
- Enrolment
- 404
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial HemorrhagesInterventionLabetalol Hydrochloride; Metoprolol tartrate; Hydralazine Hydrochloride; Glycerol Trinitrate +7 morePhaseNot applicableRegistry statusCompleted